Browsing: Anavex

The six-nominee board challenge remains pending; a September 24 vote could change Anavex’s board, but no governance change is disclosed yet.

ANAVEX LIFE SCIENCES CORP. (AVXL) reported a sharp improvement in results for the quarter ended June 30, 2026, driven by large reversals of share-based compensation after the former CEO’s termination. Operating expenses turned into a $6.7 million recovery versus $14.5 million of expenses a year earlier, and net income was $7.8 million (basic and diluted $0.08 per share)…

ANAVEX LIFE SCIENCES CORP. (AVXL) filed an amended annual report to revise its assessment of internal control over financial reporting as of September 30, 2025. After a Special Committee review and the April 30, 2026 termination of the former CEO’s employment for Cause, management and the Audit Committee concluded a material weakness existed at September…

ANAVEX LIFE SCIENCES CORP. (AVXL) filed an Amendment No. 1 to its Form 10‑Q for the quarter ended December 31, 2025. After a review overseen by a special committee and the Audit Committee, management reassessed disclosure controls and internal control over financial reporting as of that date.